on June 1, 2006
Published online before print June 1, 2006, doi: 10.1161/01.STR.0000226991.27540.f2
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on March 11, 2006
From the Department of Physiology & Pharmacology (N.S., H.Y., J.W.C., J.Z.), and the Departments of Neurosurgery and Anesthesiology (G.M., J.Z.), Loma Linda University School of Medicine, Loma Linda, Calif; and the Neurosurgery Hirosaki University (N.S., H.O.), Hirosaki, Japan. * To whom correspondence should be addressed. E-mail: johnzhang3910{at}yahoo.com.
Background and Purpose--Recent studies have shown that selective inhibition of specific subsets of intercellular adhesion molecules protects the brain during ischemia. We studied selective inhibition of integrin Methods--Rats were treated before and after MCAO with cRGDfV. Physiological parameters, expression of integrin Results--Treatment with cRGDfV reduced infarction, reduced brain edema, reduced exudation of Evans blue and IgG, and prevented fibrinogen deposition. Western blotting showed reduction of phosphorylated Flk-1 (a vascular endothelial growth factor [VEGF] receptor), reduction of phosphorylated FAK (an intracellular kinase phosphorylated in the presence of VEGF), reduction of VEGF, and reduction of fibrinogen in the cRGDfV treatment group. Conclusions--The selective integrin
Accepted on April 11, 2006
Inhibition of Integrin
Norihito Shimamura MD; 
v
3 Ameliorates Focal Cerebral Ischemic Damage in the Rat Middle Cerebral Artery Occlusion Model
v
3 with cyclo [Arg-Gly-Asp-D-Phe-Val] (cRGDfV) in the rat middle cerebral artery occlusion model (MCAO).v3, infarction volume, brain water content, Evans Blue exudation, IgG exudation, histology, immunohistochemistry, and western blotting were studied in 4 groups of animals: sham operation (n=13), untreated (n=18), nonfunctioning peptide treatment (n=19), and cRGDfV treatment (n=27).v3 inhibitor cRGDfV improves outcomes in the MCAO model by preserving the blood-brain barrier, which mechanistically may occur in a VEGF- and VEGF-receptor-dependent manner.
Key words: cerebral ischemia • fibrinogen • integrin
v3 •
VEGF
This article has been cited by other articles:
 |
|
 |
|
  J. W. Kiessling, D. B. Cines, A. A.-R. Higazi, and W. M. Armstead Inhibition of integrin {alpha}V{beta}3 prevents urokinase plasminogen activator-mediated impairment of cerebrovasodilation after cerebral hypoxia/ischemia Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H862 - H867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Jin, K. Arai, Y. Murata, S. Wang, M. F. Stins, E. H. Lo, and K. van Leyen Protecting Against Cerebrovascular Injury: Contributions of 12/15-Lipoxygenase to Edema Formation After Transient Focal Ischemia Stroke, September 1, 2008; 39(9): 2538 - 2543. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kurozumi, J. Hardcastle, R. Thakur, M. Yang, G. Christoforidis, G. Fulci, F. H. Hochberg, R. Weissleder, W. Carson, E. A. Chiocca, et al. Effect of Tumor Microenvironment Modulation on the Efficacy of Oncolytic Virus Therapy J Natl Cancer Inst, December 5, 2007; 99(23): 1768 - 1781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Rhim and G. Tosato Targeting the Tumor Vasculature to Improve the Efficacy of Oncolytic Virus Therapy J Natl Cancer Inst, December 5, 2007; 99(23): 1739 - 1741. [Full Text] [PDF]
|
|
|
|
|
|
N. Sakellaridis and D. Panagopoulos Significance of Experimental Infarct Size as an Indicator of Therapeutic Efficacy in Humans Stroke, September 1, 2007; 38(9): e89 - e90. [Full Text] [PDF]
|
|